SAN FRANCISCO, California (September 22, 2025) — Grove AI, a company advancing the next generation of clinical trials with agentic artificial intelligence (AI), will participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum. On Wednesday, September 24 2025, conference attendees can join the session “Is Pharma's Use of AI a Headwind or a Tailwind for Life Science Tools Companies and Other Potential Partners?” from 2:00 – 2:40 PM ET. The panel will be moderated by Eve Burstein, Senior Analyst (US Life Science Tools and Diagnostics Analyst) at Bernstein. Joining the conversation are Tran Le, Co‑founder and CEO of Grove AI, and Maria Pineda, Co-founder and CEO of Envisagenics. The discussion will explore how agentic AI is reshaping drug discovery, clinical development, and clinical trial operations. Attendees will hear how Grove AI’s agentic AI Digital Staff platform streamlines clinical trial operations using AI agents.